<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="236">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841605</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0458</org_study_id>
    <nct_id>NCT02841605</nct_id>
  </id_info>
  <brief_title>Enteric Nervous System in Alzheimer Disease</brief_title>
  <acronym>ENTEROMA</acronym>
  <official_title>Enteric Nervous System in Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The close homology between the central and enteric nervous systems suggests that a disease&#xD;
      process affecting the central nervous system could also involve its enteric counterpart. The&#xD;
      investigators have recently shown in that the enteric neurons can be readily analyzed using&#xD;
      routine colonic biopsies. This led us to propose that the enteric nervous system could&#xD;
      represent a unique window to assess the neuropathology in living patients with a&#xD;
      neurodegenerative disorder. The investigators have already used this approach to show that&#xD;
      Parkinson's disease pathology was recapitulated in a single colonic biopsy. By contrast to&#xD;
      Parkinson's disease, the detection of Alzheimer's disease (AD) pathology in the enteric&#xD;
      neurons has so far failed. This may be due to the low number of human tissue samples in&#xD;
      addition to the low sensitivity of the immunohistochemical methods that were used. The aim of&#xD;
      the current research project will be therefore to reevaluate AD pathology in a large number&#xD;
      of human colonic samples using both a morphological and biochemical approach .&#xD;
&#xD;
      The enteric nervous system could represent a unique window to assess the neuropathology in&#xD;
      living patients with AD. This might open the way to the development of novel AD biomarkers&#xD;
      that will directly assess the neuropathological process.&#xD;
&#xD;
      Main Aim : To Analyze the presence of beta-amyloid pathology in the enteric nervous system&#xD;
      (ENS) in AD patients&#xD;
&#xD;
      Secondary Aim(s):&#xD;
&#xD;
        1. To analyze and describe the presence of tau in the enteric nervous system (ENS) in AD&#xD;
           patients&#xD;
&#xD;
        2. To assess neuronal loss in submucosal tissue in AD patients.&#xD;
&#xD;
        3. To examine Glia cells in the enteric nervous system in AD patients..&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry</measure>
    <time_frame>4 months</time_frame>
    <description>Alpha synuclein will be analysed by means of immunohistochemistry in colonic biopsy of patients with Alzheimer disease contrasted to patients with Parkinson disease, progressive supranuclear palsy and to patients eligible for colorectal cancer screening, as a possible biomarker of AD mirroring the cerebral anomaly.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>AD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>AD group: rectosigmoidospcopy with biopsies of colon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PD group: rectosigmoidospcopy with biopsies of colon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSP group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PSP group: rectosigmoidospcopy with biopsies of colon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient eligible for colorectal cancer screening</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectosigmoidoscopy with colonic biopsies</intervention_name>
    <description>Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP</description>
    <arm_group_label>AD group</arm_group_label>
    <arm_group_label>PD group</arm_group_label>
    <arm_group_label>PSP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy with colonic biopsies</intervention_name>
    <description>Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer</description>
    <arm_group_label>Patient eligible for colorectal cancer screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - AD group : Patient with early to moderate Alzheimer disease (continuum of patients with&#xD;
        MCI due to AD and patients diagnosed with probable AD) according to NIA NAA criteria MMSE&#xD;
        score ≥18; Has one informant or care partner; No parkinsonian syndrome No sign of lewy Body&#xD;
        dementia&#xD;
&#xD;
        - PD group (control group 1) : Patients with Parkinson Disease according UKPDSBB criteria,&#xD;
        No dementia sign or cognitive deficit associated to AD&#xD;
&#xD;
        - PSP group (control group 2): Patients with possible or probable Progressive supranuclear&#xD;
        palsy group PSP according to NINDS criteria Has one informant or care partner;&#xD;
&#xD;
        - Patient eligible for colorectal cancer screening (control group 3) : No history or&#xD;
        current neurological/degenerative condition (e.g, lewy body dementia, PD, Parkinsonian&#xD;
        syndrome, AD…) No memory complaint with a Mac Nair score ≤15 MMSE score ≥28 ; Patient at&#xD;
        risk of colic cancer with a colonoscopy scheduled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - For all groups: History of colonic disorder (e.g inflammatory condition, adenocarcinoma)&#xD;
        History of bleeding disorder Traitement anticoagulant ou antiagrégant en cours Treatment&#xD;
        with anticoagulant or Platelet aggregation inhibiting drugs&#xD;
&#xD;
        - Patient with AD, PSP, PD: Any neurological/neurodegenerative condition different from the&#xD;
        group to which it belongs (e.g other than AD for AD group or other than PD for PD group….)&#xD;
&#xD;
        - Patient eligible for colorectal cancer screening Any neurological/neurodegenerative&#xD;
        condition (e.g lewy body dementia, Parkinsonian syndrome, PD, AD..)..&#xD;
&#xD;
        Functional colopathy or Irritable Bowel Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pascal Derkinderen, Professor</last_name>
    <phone>(33) 2 40 16 52 02</phone>
    <email>Pascal.derkinderen@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia Barbin</last_name>
    <phone>(33) 2 40 16 59 42</phone>
    <email>laetitia.barbin@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascal Derkinderen, Professor</last_name>
      <phone>(33) 2 40 16 52 02,</phone>
      <email>Pascal.derkinderen@chu-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

